# Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

> **NCT04815902** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Steadman Philippon Research Institute** · enrollment: 100 (estimated)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** Fisetin
- **DRUG:** Losartan
- **DRUG:** Placebo - Losartan
- **DRUG:** Placebo Fisetin

## Key facts

- **NCT ID:** NCT04815902
- **Lead sponsor:** Steadman Philippon Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-18
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04815902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04815902, "Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04815902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*